Observational studyJournal of the American Heart Association2025
Intensive Glycemic Treatment Mitigates Cardiovascular and Mortality Risk Associated With Cardiac Autonomic Neuropathy in Type 2 Diabetes.
Observational study in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting risk factors and strategies for prevention of peripheral neuropathy: focus on B-vitamin deficiencies and metabolic diseases.Neurological research and practice · 2026Review
- From Beat to Risk: How Heart Rate Variability Predicts Arrhythmias in Type 2 Diabetes.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperglycemia is one of the proposed risk factors for cardiac autonomic neuropathy (CAN). CAN is associated with increased cardiovascular and mortality risk. But it remains unclear whether cardiovascular and mortality risk associated with CAN is mitigated by intensive glycemic treatment. METHODS AND
resultsThis secondary analysis included 7866 patients from the ACCORDION (Action to Control Cardiovascular Risk in Diabetes Follow-On) study. CAN was defined using ECG-derived measures. End points included primary outcome (composite of cardiovascular events) and total deaths. During a median follow-up of 8.9 years, a total of 1341 cardiovascular events and 1364 all-cause deaths were ascertained. Compared with standard treatment, intensive treatment reduced risk of primary outcome and total deaths among patients with CAN but not among those without CAN. Compared with absence of CAN, the presence of CAN was associated with increased risk of primary outcome and total deaths in the standard group but not in the intensive group. Significant interactions were found between CAN status and treatment arms on risk of primary outcome and total deaths. Incidence rates per 100 person-years of primary outcome and total deaths were similar between patients without CAN and those with CAN undergoing intensive treatment.
conclusionsIntensive glycemic treatment mitigates cardiovascular and mortality risk associated with CAN and may serve as an effective way in the management of CAN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.